AI assistant
Sending…
Marker Therapeutics, Inc. — Director's Dealing 2004
May 27, 2004
35150_dirs_2004-05-27_ba195335-243d-4dc0-9911-6be7d9918603.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: GENEMAX CORP (gmxx.ob)
CIK: 0001094038
Period of Report: 2004-05-10
Reporting Person: Farrauto Edward (Chief Financial Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Common Stock Options | $0.7 | 2009-06-30 | Common Stock (100000) | Indirect |
More from Marker Therapeutics, Inc.
Interim / Quarterly Report
2026
May 15
Proxy Solicitation & Information Statement
2026
Mar 20
Annual Report
2026
Mar 20
Proxy Solicitation & Information Statement
2026
Mar 20
Annual Report
2026
Mar 18
Regulatory Filings
2026
Feb 9
Director's Dealing
2025
Nov 19
Director's Dealing
2025
Nov 19
Director's Dealing
2025
Nov 19
Major Shareholding Notification
2025
Nov 17